Day: June 17, 2020

Suominen Corporation’s press release on June 17, 2020 at 2:00 p.m. (EEST)Suominen has developed a nonwoven material for the manufacturing of face mask applications. The new nonwoven has passed European Standard EN 14683:2019 Type II requirements in terms of filtration efficiency and pressure drop.“Our FIBRELLA® Shield nonwoven has excellent filtration efficiency and pressure drop values meaning that the material provides protection while being comfortable and easy to breathe through. Measured with an applied method by VTT* results indicate that FIBRELLA® Shield nonwoven’s filtration efficiency is higher than 99% reaching type II requirements but of course the material can also be used for lighter model Type I masks or uncertified masks,” says Category Manager Johanna Sirén.“FIBRELLA® Shield has received positive feedback from several...

Suominen Oyj:n lehdistötiedote 17.6.2020 klo 14.00Suominen on kehittänyt kuitukangasmateriaalin hengityssuojainten valmistukseen. Uusi kuitukangas täyttää eurooppalaisen standardin EN 14683:2019 tyypin II -suojainta koskevat vaatimukset suodatustehokkuuden ja painehäviön osalta.”Suomisen FIBRELLA® Shield -kuitukankaan suodatustehokkuus on erinomainen ja painehäviö pieni. Tämä viittaa siihen, että materiaali suojaa tehokkaasti ja sen läpi on helppo ja mukava hengittää. VTT:n* sovelletulla menetelmällä todennetut tulokset osoittavat, että FIBRELLA® Shield -kankaan suodatustehokkuus on yli 99 prosenttia, yltäen siis tyypin II vaatimuksiin, mutta materiaalia voidaan toki käyttää myös kevyempien tyypin I suojainten sekä luokittelemattomien niin sanottujen kansanmaskien valmistuksessa”, Category Manager Johanna Sirén toteaa.”FIBRELLA® Shield...

Panel, including SVP of Corporate Development, Jeremy Segal, to provide practical insights on growth and exit strategiesBEDFORD, Mass., June 17, 2020 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of application development and digital experience technologies, today announced that Jeremy Segal, Senior Vice President of Corporate Development, will participate in the World Financial Symposiums’ Growth & Exit Strategies (WFS GXS) for Software and IT Companies: Managing & Selling During a Crisis – a virtual conference for Tech CEOs, founders, executives and investors.As the flagship WFS technology conference, WFS GXS for Software and IT Companies Conference 2020 typically explores critical topics in Tech M&A, such as investments, growth strategy, buyouts, sales and mergers. Due to the global pandemic,...

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 8:30 a.m. ET.A live audio webcast of the presentation will be available here and on the Company’s website at www.arvinas.com. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies...

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting accelerated approval of umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). The FDA previously granted umbralisib breakthrough therapy designation (BTD) for MZL and orphan drug designation (ODD) for MZL and FL.Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “The completion of this NDA submission marks an...

HERZLIYA, Israel, June 17, 2020 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of Secure Access solutions for on-premise and hybrid cloud environments, today announced that its wholly owned subsidiary, NetNut Ltd., has launched its Data Center proxy network.The new proxy network, built on agreements and connectivity with leading carriers in the United States, will allow NetNut’s customers to enjoy a fast, reliable and robust proxy solution upon which users can build and expand their businesses and target reach.NetNut is releasing this product as part of its long-term plans to provide the best-of-breed solution in the proxy market. This product will be added to NetNut’s existing leading Residential Proxy product and will allow customers to choose the best fit for their needs.NetNut plans to expand the Data...

TORONTO and CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, and its collaborator BC Neuroimmunology Lab Inc. (BCNI), have created a highly accurate antibody test for SARS CoV-2. In validation testing, the serology assay achieved accuracy comparable to that of the industry leaders. Incorporation of ProMIS’ proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity.The antibody test developed in collaboration with BCNI is based on the use of surface plasmon resonance (SPR) technology, a sophisticated nanotechnology platform that offers...

 AFM24, designed to activate innate immunity to broadly target EGFR-expressing solid tumors regardless of mutational status, has the potential to improve efficacy and safety over currently available EGFR-targeted therapiesAFM24 is the first innate cell redirecting immuno-oncology therapeutic dosed in solid tumor patientsThe 2nd dose cohort is open for patient recruitmentHeidelberg, Germany, June 17, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the successful completion of the first dose cohort in a Phase 1/2a clinical trial of AFM24. This first-in-human study evaluates AFM24 as monotherapy in patients with advanced solid EGFR expressing malignancies whose disease has progressed after treatment with previous anticancer...

Sievi Capital OyjLehdistötiedote 17.6.2020 klo 13.25Sievi Capitalin sijoituskohde KH-Koneet Group jatkaa laajentumistaan Ruotsissa ostamalla maanrakennuskonevuokraamo S-RentalinKH-Koneet Group on ostanut ruotsalaisen maanrakennuskonevuokraamo S-Rental AB:n koko osakekannan. Yritysosto vahvistaa KH-Koneet Groupin palvelukokonaisuutta ja asemaa Ruotsin markkinalla sekä tukee yhtiön pohjoismaiseen laajentumiseen tähtäävän strategian toteuttamista.S-Rental on vuonna 2016 perustettu ruotsalainen maansiirtokoneiden vuokraukseen erikoistunut yhtiö. Yhtiö on kasvanut perustamisestaan lähtien nopeasti ja sen liikevaihto elokuussa 2019 päättyneellä tilikaudella oli 52 miljoonaa Ruotsin kruunua. S-Rentalin toimitilat sijaitsevat Enköpingissä ja yhtiö työllistää noin 15 henkilöä. Ennen toteutunutta yrityskauppaa yhtiön omistivat Törnells Maskinuthyrning...

TORONTO, June 17, 2020 (GLOBE NEWSWIRE) — MacDonald Mines Exploration Ltd. (TSX-V: BMK) (“MacDonald Mines”, “MacDonald” or the “Company”) reports the remaining assay results from its Winter 2020 drilling program and results from 3 holes of its Spring 2020 drilling program at the SPJ Property, 20 km east of Sudbury, Ontario. Hole 41 intersected 27.2 g/t gold over 5.13 m in a new, near-surface discovery in the western extension of the New Zone-Villeneuve trend. Hole 43 intersected 2.3 g/t gold over 6.04 m and 2.1 g/t gold over 3.08 m in the New Zone-Villeneuve trend extending the zone of near-surface mineralization discovered in SM-19-022 (Dec. 9, 2019 News Release). The mineralization in the New Zone-Villeneuve trend has been traced over more than 225 metres along strike and remains open along strike and to depth.  These initial...